Read this company snapshot
Daily valuation snapshot
Pasithea Therapeutics Corp. Common Stock: source evidence dated 2026-10-09.
- Daily close (USD)
- $0.47
- Market capitalization (USD)
- $15,621,254.44
- Price / earnings (TTM)
- Not reported
- Price / book
- 0.31
The source values and product destination above identify the example to inspect.
What business is this, and what does its dated valuation mean?
Check the market day first. P/E uses trailing earnings; book value and market capitalization answer different questions.
Daily valuation dataset and column definitionsOpen the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research KTTA in the app
Open the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research KTTA in the appKeep reporting dates and units beside the answer, and inspect its original citations.
Company overview
Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven tumors, such as BRAFv600 and BRAF fusion tumors; and ETS2 driven diseases, including inflammatory bowel disease (IBD), primary sclerosing cholangitis, and ankylosing spondylitis. The company's lead development candidate is PAS-003, to treat amyotrophic lateral sclerosis. It also intends to develop PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.
Daily valuation snapshot
See the complete daily valuation snapshot
These values come from the daily market snapshot dated 2026-10-09. TTM means trailing twelve months. Use the market date when comparing KTTA with another company.
Scroll sideways to compare all columns. Select a heading to sort.
| Daily close (USD) | $0.47 |
| Market capitalization (USD) | $15,621,254.44 |
| Price / earnings (TTM) | Not reported |
| Price / book | 0.31 |
No matching rows. Clear the filter to see all records.
Read KTTA's valuation metrics
Company size
Pasithea Therapeutics Corp. Common Stock's recorded market capitalization is $15,621,254.44. It measures the market value of the company's equity, rather than its revenue or cash balance.
Price relative to earnings
P/E compares share price with trailing annual earnings per share. For a company with losses, inspect the earnings figures directly rather than treating a negative multiple as a cheap valuation.
Price relative to book equity
KTTA's recorded price-to-book ratio is 0.31. That compares its market equity value with recorded book equity. Examine its business and balance sheet to understand why those values differ.
Research Pasithea Therapeutics Corp. Common Stock with Aurora
Use the snapshot above to ask a specific question about KTTA. Ask for the report period and the figures behind the explanation, then compare the answer with the company's business description.
Continue the research
Follow KTTA's ownership disclosures to see who filed a transaction or position and when it became public. To turn a research idea into a strategy, define an entry rule and test its dated observations.